257 related articles for article (PubMed ID: 8573606)
1. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
3. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
Hofstra RM; van der Luijt RB; Lips CJ
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
[TBL] [Abstract][Full Text] [Related]
4. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations.
Rossel M; Pasini A; Chappuis S; Geneste O; Fournier L; Schuffenecker I; Takahashi M; van Grunsven LA; Urdiales JL; Rudkin BB; Lenoir GM; Billaud M
Oncogene; 1997 Jan; 14(3):265-75. PubMed ID: 9018112
[TBL] [Abstract][Full Text] [Related]
5. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
6. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
[TBL] [Abstract][Full Text] [Related]
7. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
Kawai K; Iwashita T; Murakami H; Hiraiwa N; Yoshiki A; Kusakabe M; Ono K; Iida K; Nakayama A; Takahashi M
Cancer Res; 2000 Sep; 60(18):5254-60. PubMed ID: 11016655
[TBL] [Abstract][Full Text] [Related]
8. The physical map of the human RET proto-oncogene.
Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
J Intern Med; 1998 Jun; 243(6):509-13. PubMed ID: 9681851
[TBL] [Abstract][Full Text] [Related]
10. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.
Maruyama S; Iwashita T; Imai T; Funahashi H; Ceccherini I; Luo Y; Romeo G; Matsuo S; Matsuyama M; Takahashi M
Jpn J Cancer Res; 1994 Sep; 85(9):879-82. PubMed ID: 7961113
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
12. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
Sansó G; Domené HM; Iorcansky S; Barontini M
Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
[TBL] [Abstract][Full Text] [Related]
13. The RET protooncogene in sporadic pheochromocytomas: frequent MEN 2-like mutations and new molecular defects.
Beldjord C; Desclaux-Arramond F; Raffin-Sanson M; Corvol JC; De Keyzer Y; Luton JP; Plouin PF; Bertagna X
J Clin Endocrinol Metab; 1995 Jul; 80(7):2063-8. PubMed ID: 7608256
[TBL] [Abstract][Full Text] [Related]
14. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.
Vidal M; Wells S; Ryan A; Cagan R
Cancer Res; 2005 May; 65(9):3538-41. PubMed ID: 15867345
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnosis of multiple type 2 endocrine neoplasia].
Amosenko FA; Pushkash K; Frilling A; Kozlova VN; Liubchenko LN; Kazubskaia TP; Brelysh KE; Gar'kavtseva RF; Kalinin VN
Vestn Ross Akad Med Nauk; 2001; (2):34-7. PubMed ID: 11338505
[TBL] [Abstract][Full Text] [Related]
16. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
17. "Cold" single-strand conformational variants for mutation analysis of the RET protooncogene.
Musholt PB; Musholt TJ; Goodfellow PJ; Zehnbauer BA; Wells SA; Moley JF
Surgery; 1997 Aug; 122(2):363-70; discussion 370-1. PubMed ID: 9288142
[TBL] [Abstract][Full Text] [Related]
18. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.
Michiels FM; Chappuis S; Caillou B; Pasini A; Talbot M; Monier R; Lenoir GM; Feunteun J; Billaud M
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3330-5. PubMed ID: 9096393
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement.
Rabes HM; Klugbauer S
Recent Results Cancer Res; 1998; 154():248-64. PubMed ID: 10027005
[TBL] [Abstract][Full Text] [Related]
20. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
